Interaction Checker

As cookies ajudam-nos a oferecer os nossos serviços. Ao utilizar os nossos serviços, aceita o uso de cookies. Mais informações

New primary drug, HCV DAA Ravidsavir

Thursday 31 August 2023

We have added Ravidasvir (Ravida®) to the drug interaction checker, in our first addition to the lineup of Direct Acting Antivirals for many years. 

Ravidasvir is an NS5A inhibitor approved for use with sofosbuvir, which achieved a 97% cure rate in clinical trials in Malaysia. Ravidasvir is an affordable medication, that will expand access to an HCV cure to low-to-middle-income countries. Ravidasvir does not interact with CYP enzymes but is a P-gp substrate, so coadministration with strong P-gp inducers is contraindicated and coadministration with moderate P-gp inducers is not recommended.

Our thanks to DNDi for providing pharmacokinetic data to assist with writing the drug interactions.

Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016